We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
76
X4 Pharmaceuticals
XFOR
$368M
$13.8M 0.25%
237,784
+43,860
+23% +$2.25M
BAX icon
77
CALL
Baxter International
BAX
$12.7B
$13.7M 0.25%
300,000
-50,000
-14% -$2.18M
KZR
78
DELISTED
Kezar Life Sciences
KZR
$13.4M 0.24%
546,300
– –
JBIO
79
Jade Biosciences
JBIO
$1.16B
$13M 0.24%
21,627
– –
ARGX icon
80
argenx
ARGX
$55.2B
$12.7M 0.23%
32,600
-11,900
-27% -$4.68M
MORF
81
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$12M 0.22%
+208,500
New +$10.9M
VSTM icon
82
Verastem
VSTM
$520M
$11.4M 0.21%
1,529,115
+153,845
+11% +$1.07M
HUM icon
83
CALL
Humana
HUM
$43.8B
$11.2M 0.2%
+25,000
New +$12.6M
IMTX icon
84
Immatics
IMTX
$1.18B
$11.2M 0.2%
966,829
+19,581
+2% +$183K
GDRX icon
85
GoodRx Holdings
GDRX
$1.06B
$9.87M 0.18%
1,788,600
+88,600
+5% +$477K
REGN icon
86
Regeneron Pharmaceuticals
REGN
$73B
$9.7M 0.18%
13,500
-10,500
-44% -$8.1M
DMRA
87
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.76B
$9.66M 0.18%
153,369
-10,268
-6% -$559K
PASG icon
88
Passage Bio
PASG
$14.2M
$9.53M 0.17%
506,229
+59,629
+13% +$1.18M
AKRO
89
DELISTED
Akero Therapeutics
AKRO
$9.31M 0.17%
+199,500
New +$9.14M
ORIC icon
90
Oric Pharmaceuticals
ORIC
$1.17B
$9.07M 0.16%
1,168,468
-206,000
-15% -$1.17M
GHRS icon
91
GH Research
GHRS
$1.91B
$8.74M 0.16%
736,315
-922,700
-56% -$9.46M
THC icon
92
CALL
Tenet Healthcare
THC
$22.4B
$8.14M 0.15%
+100,000
New +$7.12M
GILD icon
93
Gilead Sciences
GILD
$166B
$7.71M 0.14%
+100,000
New +$7.98M
MLTX icon
94
MoonLake Immunotherapeutics
MLTX
$1.58B
$5.97M 0.11%
+117,000
New +$3.15M
LSB
95
DELISTED
LakeShore Biopharma
LSB
$5.93M 0.11%
429,847
+1
+0% +$15
CGEM icon
96
Cullinan Oncology
CGEM
$1.03B
$5.86M 0.11%
544,848
-60,539
-10% -$643K
CUTR
97
DELISTED
Cutera, Inc.
CUTR
$5.86M 0.11%
+387,100
New +$7.33M
SRRK icon
98
Scholar Rock
SRRK
$5.89B
$5.55M 0.1%
735,645
+220,645
+43% +$1.67M
IVVD icon
99
Invivyd
IVVD
$167M
$5.53M 0.1%
5,270,400
– –
HZNP
100
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.14M 0.09%
50,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.